Praxis Precision Medicines Sees Q4 2025 Loss of $3.08, 2026 Sales Forecast Rises to $15.38M
Praxis Precision Medicines is forecast to post Q4 2025 revenue of $0.04M and a loss of $3.08 per share, with 2025 revenue at $0.04M and EPS -$13.05. Analysts have raised 2026 revenue estimates from $5.92M to $15.38M in 90 days, while average price targets stand at $572.88 implying 74.7% upside.
1. Q4 2025 Earnings Estimates Preview
Praxis Precision Medicines is set to report Q4 2025 revenue of $0.04 million and an EPS loss of $3.08. For the full year 2025, revenue is expected at $0.04 million with EPS of -$13.05. In Q3 2025 the company reported zero revenue and a $3.36 loss per share, missing revenue expectations by 100% but slightly beating EPS estimates.
2. 2026 Revenue and Earnings Estimate Trends
Over the past 90 days, revenue estimates for 2026 have climbed from $5.92 million to $15.38 million, reflecting increased confidence in late-stage clinical progress. Conversely, full-year 2026 EPS forecasts have slipped from -$12.72 to -$13.17, indicating anticipated higher R&D spending.
3. Analyst Price Targets, GF Value and Recommendations
Sixteen analysts set an average one-year price target of $572.88, ranging from $95.00 to $1,245.00 and implying 74.7% upside. Proprietary fair value estimates place the stock at $313.14, suggesting 4.5% downside. The consensus brokerage recommendation stands at 1.9, signaling an "Outperform" rating.